Effectiveness of the Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters in Pregnant Persons Who Were Not Immunocompromised: VISION Network, June 2022-August 2023

Allison Avrich Ciesla; Victoria Lazariu; Kristin Dascomb; Stephanie A Irving; Brian E Dixon; Manjusha Gaglani; Allison L Naleway; Shaun J Grannis; Sarah Ball; Anupam B Kharbanda; Gabriela Vazquez-Benitez; Nicola P Klein; Karthik Natarajan; Toan C Ong; Peter J Embi; Katherine E Fleming-Dutra; Ruth Link-Gelles; Ousseny Zerbo

doi:10.1093/ofid/ofae481

Effectiveness of the Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters in Pregnant Persons Who Were Not Immunocompromised: VISION Network, June 2022-August 2023

Open Forum Infect Dis. 2024 Aug 28;11(9):ofae481. doi: 10.1093/ofid/ofae481. eCollection 2024 Sep.

Authors

Allison Avrich Ciesla^{1

2}, Victoria Lazariu³, Kristin Dascomb⁴, Stephanie A Irving⁵, Brian E Dixon^{6

7}, Manjusha Gaglani^{8

9

10}, Allison L Naleway⁵, Shaun J Grannis^{6

11}, Sarah Ball³, Anupam B Kharbanda¹², Gabriela Vazquez-Benitez¹³, Nicola P Klein¹⁴, Karthik Natarajan^{15

16}, Toan C Ong¹⁷, Peter J Embi¹⁸, Katherine E Fleming-Dutra¹, Ruth Link-Gelles^{1

19}, Ousseny Zerbo¹⁴

Affiliations

¹ Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
² Eagle Health Analytics, San Antonio, Texas, USA.
³ Westat, Rockville, Maryland, USA.
⁴ Division of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, Utah, USA.
⁵ Kaiser Permanente Center for Health Research, Portland, Oregon, USA.
⁶ Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
⁷ Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana, USA.
⁸ Section of Pediatric Infectious Diseases, Department of Pediatrics, Baylor Scott & White Health, Temple, Texas, USA.
⁹ Department of Pediatrics, Baylor College of Medicine, Temple, Texas, USA.
¹⁰ Department of Medical Education, Texas A&M University College of Medicine, Temple, Texas, USA.
¹¹ School of Medicine, Indiana University, Indianapolis, Indiana, USA.
¹² Children's Minnesota, Minneapolis, Minnesota, USA.
¹³ HealthPartners Institute, Minneapolis, Minnesota, USA.
¹⁴ Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California, USA.
¹⁵ Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.
¹⁶ NewYork-Presbyterian Hospital, New York, New York, USA.
¹⁷ School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
¹⁸ Vanderbilt University Medical Center, Nashville, Tennessee, USA.
¹⁹ US Public Health Service Commissioned Corps, Rockville, Maryland, USA.

Abstract

Pregnant people face increased risk of severe COVID-19. Current guidelines recommend updated COVID-19 vaccination (2023-2024) for those aged ≥6 months, irrespective of pregnancy status. To refine recommendations for pregnant people, further data are needed. Using a test-negative design, we evaluated COVID-19 vaccine effectiveness against medically attended COVID-19 with COVID-19-like illness among pregnant people aged 18 to 45 years during June 2022 to August 2023. When doses were received during pregnancy, vaccine effectiveness was 52% (95% CI, 29%-67%); when received <6 months prior to pregnancy, 28% (95% CI, 11%-42%); and when received ≥6 months prior to pregnancy, 6% (95% CI, -11% to 21%). Pregnant people should stay up-to-date with recommended COVID-19 vaccination.

Keywords: COVID-19; SARS-CoV-2; pregnant persons; public health; vaccine effectiveness.

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2024.